natgillin/translations-raw huggingface dataset:
Abraxane was administered to patients (N = 431) as an intravenous infusion over 30-40 minutes at a dose of 125 mg/m2 followed by gemcitabine as an intravenous infusion over 30-40 minutes at a dose of 1000 mg/m2 given on Days 1, 8 and 15 of each 28-day cycle. 
Zdravilo Abraxane so dajali bolnikom (N = 431) v obliki intravenske infuzije v času 30-40 minut v odmerku 125 mg/m2, nato je sledil gemcitabin v obliki intravenske infuzije v času 30-40 minut v odmerku 1.000 mg/m2, ki so ga bolniki prejemali 1., 8. in 15. dan vsakega 28-dnevnega cikla.
The following are the most common and important incidences of adverse reactions related to 421 patients with metastatic adenocarcinoma of the pancreas who were treated with 125 mg/m2 Abraxane in combination with gemcitabine at a dose of 1000 mg/m2 given on Days 1, 8 and 15 of each 28-day cycle in the phase III clinical study. 
V nadaljevanju so navedena najpogostejša in najpomembnejša pojavljanja neželenih učinkov pri 421 bolnikih z metastatskim adenokarcinomom trebušne slinavke, zdravljenih s 125 mg/m2 zdravila Abraxane v kombinaciji z gemcitabinom v odmerku 1.000 mg/m2 1., 8. in 15. dan vsakega 28dnevnega cikla v klinični študiji faze III.
Women of childbearing potential should have a pregnancy test prior to starting treatment with Abraxane. 
Ženske v rodni dobi morajo pred začetkom zdravljenja z zdravilom Abraxane opraviti test nosečnosti.
For combination use of Abraxane and gemcitabine, if Grade 3 or higher peripheral neuropathy develops, withhold Abraxane; continue treatment with gemcitabine at the same dose. 
Če se razvije periferna nevropatija 3. ali višje stopnje, ko se zdravilo Abraxane uporablja v kombinaciji z gemcitabinom, prekinite zdravljenje z zdravilom Abraxane; zdravljenje nadaljujte z enakimi odmerki gemcitabina.
The second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63 
Pri drugi raziskavi so uporabili odmerek 300 mg/m2 kot 30
Very common: Alopecia, rash 
Zelo pogosti: alopecija, izpuščaj
• Stuffy nose 
• zamašen nos
Peripheral Neuropathy: Grade 3 or 4 
Periferna nevropatija: 3. ali 4. stopnje
Non-small cell lung cancer (Abraxane administered in combination with carboplatin) 
Nedrobnocelični pljučni rak (zdravilo Abraxane uporabljeno v kombinaciji s karboplatinom)
Cutaneous Toxicity: Grade 2 or 3 
Toksičnost za kožo: 2. ali 3. stopnje
Breast cancer (Abraxane administered as monotherapy) 
Rak dojk (zdravilo Abraxane uporabljeno kot monoterapija)
Discontinue treatment 
Ukinite zdravljenje
No patients treated with Abraxane and carboplatin experienced Grade 4 peripheral neuropathy. 
Noben bolnik, zdravljen z zdravilom Abraxane in karboplatinom, ni imel periferne nevropatije 4. stopnje.
Reconstituted Abraxane suspension is administered intravenously using an infusion set incorporating a 15 µm filter. 
Rekonstituirano suspenzijo zdravila Abraxane dajajte intravensko z infuzijskim sistemom, ki vključuje 15 µm filter.
When reconstituted, each ml of Abraxane concentrate contains 0.183 mmol sodium, which is 4.2 mg of sodium. 
Po rekonstituciji 1 ml koncentrata zdravila Abraxane vsebuje 0,183 mmola natrija, kar ustreza 4,2 mg natrija.
Abraxane contains sodium 
Zdravilo Abraxane vsebuje natrij
Very common: Dyspnoea 
Zelo pogosti: dispneja
No patients treated with Abraxane in combination with gemcitabine had Grade 4 peripheral neuropathy. 
Noben bolnik, zdravljen z zdravilom Abraxane v kombinaciji z gemcitabinom, ni imel periferne nevropatije 4. stopnje.
Overall Survival Number of deaths (%) Median Overall Survival, months (95% CI) HRA+G/G (95% CI)a P-valueb 
Celokupno preživetje Število smrti (%) Mediana celokupnega preživetja, meseci (95 % IZ) HRA+G/G (95 % IZ)a p-vrednostb
• Difficulty walking, swelling 
• težave s hojo, otekanje
The use of specialized di(2-ethylhexyl)phthalate (DEHP)-free solution containers or administration sets is not necessary to prepare or administer Abraxane infusions. 
Ni nujno, da pri pripravi ali dajanju infuzij zdravila Abraxane uporabljate specializirane vsebnike ali komplete za dajanje zdravila brez di(2-etilheksil)ftalata (DEHP).
The total combined storage time of reconstituted medicinal product in the vial and in the infusion bag when refrigerated and protected from light is 24 hours. 
V primeru shranjevanja v hladilniku in zaščiteno pred svetlobo je skupni čas shranjevanja rekonstituiranega zdravila v viali in infuzijski vrečki 24 ur.
NAME OF THE MEDICINAL PRODUCT Abraxane 5 mg/ml powder for suspension for infusion paclitaxel 
IME ZDRAVILA Abraxane 5 mg/ml prašek za suspenzijo za infundiranje
Table 9 lists adverse reactions associated with the administration of Abraxane in combination with carboplatin. 
V preglednici 9 so navedeni neželeni učinki, povezani z uporabo zdravila Abraxane v kombinaciji s karboplatinom.
Abraxane should only be prepared and administered by personnel appropriately trained in the handling of cytotoxic agents. 
Abraxane sme pripraviti in dajati le osebje, ki je ustrezno usposobljeno za rokovanje s citotoksičnimi zdravili.
Of the 514 patients with non-small cell lung cancer in the randomized study who received Abraxane in combination with carboplatin, 31% were 65 years or older and 3.5% were 75 years or older. 
Od 514 bolnikov z nedrobnoceličnim pljučnim rakom v randomizirani študiji, ki so prejemali zdravilo Abraxane v kombinaciji s karboplatinom, jih je bilo 31 % starih 65 let in več, 3,5 % pa jih je bilo starih 75 let in več.
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C in the original carton, protected from light. 
Kemična in fizikalna stabilnost po rekonstituciji sta dokazani za 24 ur pri 2 °C - 8 °C, v originalni ovojnini, zaščiteno pred svetlobo.
Table 7 lists adverse reactions assessed in patients with pancreatic adenocarcinoma treated with Abraxane in combination with gemcitabine. 
V preglednici 7 so navedeni neželeni učinki, ugotovljeni pri bolnikih z adenokarcinomom trebušne slinavke, zdravljenih z zdravilom Abraxane v kombinaciji z gemcitabinom.
Myalgia occurred in 24% of patients on Abraxane and was severe in 7% of cases. 
Mialgija se je pojavila pri 24 % bolnikov, ki so prejemali zdravilo Abraxane, od tega je bilo 7 % hudih primerov.
Abraxane is available in glass vials containing 100 mg or 250 mg of paclitaxel formulated as albumin bound nanoparticles. 
Zdravilo Abraxane je na voljo v steklenih vialah, ki vsebujejo 100 mg ali 250 mg paklitaksela, vezanega na albuminske nanodelce.
Pharmacokinetic data are not available for patients with total bilirubin >5 x ULN or for patients with metastatic adenocarcinoma of the pancreas (see section 4.2). 
Za bolnike s celokupnim bilirubinom > 5 x ULN in za bolnike z metastatskim adenokarcinomom trebušne slinavke farmakokinetični podatki niso na voljo (glejte poglavje 4.2).
Non-small cell lung cancer: 
Nedrobnocelični pljučni rak:
No toxicities occurred notably more frequently among patients at least 65 years of age who received Abraxane. 
Pri bolnikih, ki so bili stari vsaj 65 let in so prejemali zdravilo Abraxane, niso opazili pogostejše toksičnosti.
Uncommon: Oral candidiasis, nasopharyngitis, cellulitis, herpes simplex, viral infection, pneumonia, catheter-related infection, fungal infection, herpes zoster, injection site infection, sepsis2, neutropenic sepsis2 
Občasni: oralna kandidoza, nazofaringitis, celulitis, herpes simpleks, virusna okužba, pljučnica, okužbe, povezane s katetrom, glivične okužbe, pasavec, okužba na mestu vboda, sepsa2, nevtropenična sepsa2
Common: Dehydration, decreased appetite, hypokalaemia Uncommon: Hypophosphataemia, fluid retention, hypoalbuminaemia, polydipsia, hyperglycaemia, hypocalcaemia, hypoglycaemia, hyponatraemia 
Pogosti: dehidracija, zmanjšan apetit, hipokaliemija Občasni: hipofosfatemija, zadrževanje tekočine, hipoalbuminemija, polidipsija, hiperglikemija, hipokalciemija, hipoglikemija, hiponatriemija
Frequent monitoring of blood cell counts should be performed during Abraxane therapy. 
Med zdravljenjem z zdravilom Abraxane je treba pogosto preverjati število krvnih celic.
Abraxane should only be administered under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents. 
Zdravilo Abraxane se sme uporabljati samo pod nadzorom ustrezno usposobljenega onkologa v enotah, specializiranih za uporabo citotoksičnih snovi.
Abraxane should not be administered on Day 1 of a cycle until absolute neutrophil count (ANC) is ≥1500 cells/mm3 and platelet count is ≥100,000 cells/mm3. 
Zdravila Abraxane ni dovoljeno dati 1. dan cikla, če ni absolutno število nevtrofilcev (ANC) ≥1.500 celic/mm3 in število trombocitov ≥100.000 celic/mm3.
Sepsis was reported at a rate of 5% in patients with or without neutropenia who received Abraxane in combination with gemcitabine. 
O sepsi so poročali pri 5 % bolnikov z nevtropenijo ali brez nje, ki so prejemali zdravilo Abraxane skupaj z gemcitabinom.
Sepsis was reported at a rate of 5% in patients with or without neutropenia who received Abraxane in combination with gemcitabine during the conduct of a trial in pancreatic adenocarcinoma. 
O sepsi so poročali pri 5 % bolnikov z nevtropenijo ali brez nje, ki so prejemali zdravilo Abraxane v kombinaciji z gemcitabinom med preskušanjem pri adenokarcinomu trebušne slinavke.
pA+G/pG (95% CI) 
HRA+G/G (95 % IZ)a p-vrednostb
Women of childbearing potential should use effective contraception during treatment and up to 1 month after receiving treatment with Abraxane. 
Ženske v rodni dobi morajo uporabljati zanesljivo kontracepcijo med zdravljenjem z zdravilom Abraxane in do en mesec po zdravljenju.
Of the 421 patients with pancreatic adenocarcinoma in the randomized study who received Abraxane in combination with gemcitabine, 41% were 65 years and older and 10% were 75 years and older. 
Od 421 bolnikov z adenokarcinomom trebušne slinavke v randomizirani študiji, ki so prejemali zdravilo Abraxane v kombinaciji z gemcitabinom, jih je bilo 41 % starih 65 let in več, 10 % pa 75 let in več.
Common: Decreased weight, increased alanine aminotransferase, increased aspartate aminotransferase, decreased haematocrit, decreased red blood cell count, increased body temperature, increased gamma-glutamyltransferase, increased blood alkaline phosphatase 
Pogosti: zmanjšana telesna masa, zvišana alanin-aminotransferaza, zvišana aspartat-aminotransferaza, znižana vrednost hematokrita, manjše število rdečih krvnih celic, zvišana telesna temperatura, zvišana gamaglutamiltransferaza, zvišana alkalna fosfataza v krvi
The pharmacokinetics of total paclitaxel following 30- and 180-minute infusions of Abraxane at dose levels of 80 to 375 mg/m2 were determined in clinical studies. 
V kliničnih študijah je bila določena farmakokinetika celokupnega paklitaksela po 30- in 180-minutni infuziji zdravila Abraxane pri odmerkih od 80 do 375 mg/m2.
Peripheral neuropathy (mostly Grade 1 or 2 sensory neuropathy) was observed in 68% of patients on Abraxane with 10% being Grade 3, and no cases of Grade 4. 
Periferno nevropatijo (večinoma senzorično nevropatijo 1. ali 2. stopnje) so opazili pri 68 % bolnikov, ki so prejemali zdravilo Abraxane.
In some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysaesthesiae have been reported as part of the continuing surveillance of Abraxane. 
V okviru nadaljnjega spremljanja zdravila Abraxane so pri nekaterih bolnikih, ki so predhodno prejemali kapecitabin, poročali o palmarno-plantarni eritrodisesteziji.
Table 6: Adverse reactions reported with Abraxane monotherapy at any dose in clinical studies Infections and infestations 
Preglednica 6: Neželeni dogodki, o katerih so poročali pri monoterapiji z zdravilom Abraxane v katerem koli odmerku v kliničnih študijah
Abraxane should not be administered until neutrophil counts recover to >1500 cells/mm3. 
Zdravila Abraxane ni dovoljeno dajati, dokler število nevtrofilcev ne doseže vrednosti > 1.500 celic/mm3.
Abraxane (100 mg/m2/week) + carboplatin (N=521) 
Zdravilo Abraxane (100 mg/m2/teden) + karboplatin (N=521)
Abraxane should be administered under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents. 
Zdravilo Abraxane se jemlje pod nadzorom ustrezno usposobljenega onkologa v enoti, ki je specializirana za uporabo citotoksičnih snovi.
100 ml vial (type 1 glass) with a stopper (butyl rubber), with an overseal (aluminium), containing 250 mg of paclitaxel formulated as albumin bound nanoparticles. 
Viala 100 ml (steklo tipa 1) z zamaškom (butilna guma), z zaporko (aluminij), ki vsebuje 250 mg paklitaksela, vezanega na albuminske nanodelce.
Pancreatic adenocarcinoma (Abraxane administered in combination with gemcitabine) 
Adenokarcinom trebušne slinavke (zdravilo Abraxane uporabljeno skupaj z gemcitabinom)
MARKETING AUTHORISATION NUMBER(S) EU/1/07/428/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/428/001
At the clinical dose range of 80 to 300 mg/m2, the mean plasma clearance of paclitaxel ranges from 13 to 30 L/h/m2, and the mean terminal half-life ranges from 13 to 27 hours. 
V mejah kliničnih odmerkov od 80 do 300 mg/m2 je povprečni plazemski očistek paklitaksela med 13
Women of childbearing age should use effective contraception during and up to 1 month after receiving treatment with Abraxane. 
Ženske v rodni dobi morajo uporabljati zanesljivo kontracepcijo med zdravljenjem z zdravilom Abraxane in do 1 mesec po njem.
Gastrointestinal Toxicity: Grade 3 mucositis or diarrhoea 
Toksičnost za prebavila: mukozitis 3. stopnje ali driska
Uncommon: Polyneuropathy, areflexia, dyskinesia, hyporeflexia, neuralgia, sensory loss, syncope, postural dizziness, neuropathic pain, tremor 
Občasni: polinevropatija, arefleksija, diskinezija, hiporefleksija, nevralgija, senzorična izguba, sinkopa, posturalna omotičnost, nevropatska bolečina, tremor
The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer Abraxane infusions. 
Ni nujno, da pri pripravi ali dajanju infuzij zdravila Abraxane uporabljate specializirane vsebnike ali komplete za dajanje zdravila brez DEHP.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 100 mg of paclitaxel formulated as albumin bound nanoparticles. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala vsebuje 100 mg paklitaksela, vezanega na albuminske nanodelce.
The recommended dose of Abraxane is 100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of each 21-day cycle. 
Priporočeni odmerek zdravila Abraxane je 100 mg/m2, ki se daje kot intravenska infuzija v času 30 minut 1., 8. in 15. dan vsakega 21-dnevnega cikla.
Common: Insomnia, depression, anxiety Uncommon: Restlessness 
Pogosti: nespečnost, depresivnost, anksioznost Občasni: nemirnost
Beginning immediately after the end of Abraxane administration, carboplatin at a dose of AUC = 6 mg•min/mL was administered intravenously on Day 1 only of each 21-day cycle. 
Takoj po končanem dajanju zdravila Abraxane so bolnikom samo 1. dan vsakega 21-dnevnega cikla dali karboplatin intravensko v odmerku AUC = 6 mg•min/ml.
Day 15: IF Day 8 doses were withheld: Day 15 ≥ 1000 
15. dan: Če bolnik ni prejel odmerkov 8. dne: 15. dan ≥ 1.000
• Fingernail pain, fingernail discomfort, loss of fingernails, hives, skin pain, red skin from sunlight, 
• bolečine nohtov, neugoden občutek nohtov, izguba nohtov, kožna bolečina, pordela koža zaradi sončne svetlobe, razbarvanje kože, povečano znojenje, nočno znojenje, bela območja na koži,
Table 7: Adverse reactions reported with Abraxane in combination with gemcitabine (N =421) Infections and infestations 
Preglednica 7: Neželeni učinki, o katerih so poročali pri zdravilu Abraxane v kombinaciji z gemcitabinom (N =421)
Unopened vials: Keep the vial in the outer carton in order to protect from light. 
Neodprte viale: Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Solvent-based paclitaxel (200 mg/m2 every 3 weeks) + carboplatin (N=531) 
Paklitaksel na bazi topila (200 mg/m2 vsake 3 tedne) + karboplatin (N=531)
After reconstitution, each ml of suspension contains 5 mg of paclitaxel formulated as albumin bound nanoparticles. 
Po rekonstituciji vsebuje 1 ml suspenzije 5 mg paklitaksela, vezanega na albuminske nanodelce.
Cycle Day 
Dan cikla
Common: Infection, urinary tract infection, folliculitis, upper respiratory tract infection, candidiasis, sinusitis 
Pogosti: okužbe, okužbe sečil, folikulitis, okužbe zgornjih dihal, kandidoza, sinusitis
Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to >1500 cells/mm3 and platelets recover to >100,000 cells/mm3 (see section 
Nadaljnjih ciklov zdravila Abraxane ne smete začeti, dokler se nevtrofilci ne vrnejo na vrednost > 1.500 celic/mm3, trombociti pa na vrednost > 100.000 celic/mm3 (glejte poglavje 4.2).
Day 15: If Day 8 doses were given without modification: Day 15 ≥ 500 but < 1000 OR ≥ 50,000 but < 75,000 
15. dan: Če so bili odmerki 8. dne dani brez sprememb: 15. dan ≥ 500 ali
There was a significant difference in overall response rate in the Abraxane/carboplatin arm compared to the control arm in patients with non-small cell lung cancer of squamous histology (N=450, 41% vs. 24%, p<0.001), however this difference did not translate into a difference in PFS or OS. 
V skupini z zdravilom Abraxane/karboplatinom se je stopnja celokupnega odziva značilno razlikovala od kontrolne skupine pri bolnikih z nedrobnoceličnim pljučnim rakom s ploščatocelično histologijo (N=450, 41 % proti 24 %, p<0,001), vendar se ta razlika ni prenesla v razliko v PFS ali OS. Razlike v ORR med zdravljenima skupinama pri bolnikih z neploščatocelično histologijo ni bilo (N=602, 26 % proti 25 %, p=0,808).
Very common: Neutropenia, anaemia, leukopenia, thrombocytopenia, lymphopenia, bone marrow suppression Common: Febrile neutropenia 
Zelo pogosti: nevtropenija, anemija, levkopenija, trombocitopenija, limfopenija, supresija kostnega mozga Pogosti: febrilna nevtropenija
Common: Nail disorder, pruritus, dry skin, erythema, nail pigmentation/discolouration, skin hyperpigmentation, onycholysis, nail changes 
Pogosti: motnje nohtov, srbenje, suha koža, eritem, obarvanje/razbarvanje nohtov, hiperpigmentacija kože, oniholiza, spremembe nohtov
The other ingredient is human albumin (containing sodium, sodium caprylate and N-acetyl DL tryptophanate). 
Pomožna snov je humani albumin (ki vsebuje natrij, natrijev kaprilat in N-acetil DL triptofanat).
Very common: Fatigue, asthenia, pyrexia Common: Peripheral oedema, mucosal inflammation, pain, rigors, oedema, weakness, decreased performance status, chest pain, influenza-like illness, malaise, lethargy, hyperpyrexia 
Zelo pogosti: utrujenost, astenija, pireksija Pogosti: periferni edem, vnetje sluznice, bolečine, okorelost, edem, šibkost, manjša zmogljivost, bolečine v prsih, gripi podobna bolezen, slabo počutje, letargija, hiperpireksija
Very common: Arthralgia, myalgia Common: Back pain, pain in extremity, musculoskeletal pain 
Zelo pogosti: artralgija, mialgija Pogosti: bolečina v hrbtu, bolečina v udih, bolečina v mišicah in kosteh
Occurrence Dose of Abraxane (mg/m2)1 
Pojavljanje Odmerek zdravila Abraxane (mg/m2)1
The recommended dose of Abraxane in combination with gemcitabine is 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. 
Priporočeni odmerek zdravila Abraxane v kombinaciji z gemcitabinom je 125 mg/m2, ki se daje intravensko 30 minut 1., 8. in 15. dan vsakega 28-dnevnega cikla.
The usual dose is for breast cancer is 260 mg/m2 of body surface area given over a 30 minute period. 
Običajni odmerek pri raku dojk je 260 mg/m2 telesne površine.
Talk to your doctor or nurse if you experience any of these conditions whilst being treated with Abraxane, your doctor may wish to stop treatment or reduce the dose: 
Posvetujte se z zdravnikom ali medicinsko sestro, če se vam pojavijo katere koli od spodaj navedenih težav, medtem ko vas zdravijo z zdravilom Abraxane.
MARKETING AUTHORISATION NUMBER(S) EU/1/07/428/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/28/002
Very common: Rash, alopecia Common: Pruritus, nail disorder Uncommon: Skin exfoliation, dermatitis allergic, urticaria 
Zelo pogosti: izpuščaj, alopecija Pogosti: pruritus, bolezni nohtov Občasni: luščenje kože, alergijski dermatitis, urtikarija
Abraxane Dose (mg/m2) 
Odmerek zdravila Abraxane (mg/m2)
The concurrent recommended dose of gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Abraxane administration on Days 1, 8 and 15 of each 28-day cycle. 
Sočasni priporočeni odmerek gemcitabina je 1.000 mg/m2, ki se daje intravensko 30 minut takoj po končanem dajanju zdravila Abraxane 1., 8. in 15. dan vsakega 28-dnevnega cikla.
• Gas, stomach cramps, painful or sore gums, rectal bleeding 
• vetrovi, trebušni krči, bolečine ali razjede na dlesnih, krvavenje iz danke
The uncommon side effects may affect up to 1 in 100 people: 
Občasni neželeni učinki se lahko pojavijo pri največ 1 od 100 bolnikov:
Common: Lacrimation increased Uncommon: Cystoid macular oedema 
Pogosti: zvečano solzenje Občasni: cistoidni makularni edem
There were no clinically relevant pharmacokinetic interactions between Abraxane and carboplatin. 
Med zdravilom Abraxane in karboplatinom ni bilo klinično pomembnih farmakokinetičnih interakcij.
Erlotinib should not be coadministered with Abraxane plus gemcitabine (see section 4.5). 
Erlotiniba ne smete dajati skupaj s kombinacijo zdravila Abraxane in gemcitabina (glejte poglavje
• Decreased phosphorus in the blood, fluid retention, low albumin in the blood, increased thirst, 
• znižana raven fosforja v krvi, zadrževanje tekočine, znižana raven albumina v krvi, povečana žeja, znižana raven kalcija v krvi, znižana raven krvnega sladkorja, znižana raven natrija v krvi
• medicines used to treat HIV and AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, 
sakvinavir, indinavir, nelfinavir, efavirenz, nevirapin)
Human albumin solution (containing sodium, sodium caprylate and N-acetyl DL tryptophanate). 
Raztopina humanega albumina (vsebuje natrij, natrijev kaprilat in N-acetil DL triptofanat).
Table 3: Dose modifications for other adverse drug reactions in patients with pancreatic adenocarcinoma Adverse Drug Reaction (ADR) 
Preglednica 3: Prilagajanje odmerka pri drugih neželenih učinkih zdravila pri bolnikih z adenokarcinomom trebušne slinavke
Paclitaxel is a cytotoxic anticancer medicinal product and, as with other potentially toxic compounds, caution should be exercised in handling Abraxane. 
Tako kot pri drugih potencialno toksičnih spojinah je treba tudi z zdravilom Abraxane previdno ravnati.
Abraxane was administered to patients (N=521) as an intravenous infusion over 30 minutes at a dose of 100 mg/m2 on Days 1, 8 and 
Bolnikom (N=521) so dajali zdravilo Abraxane v obliki intravenske infuzije 30 minut v odmerku 100 mg/m2 1.,
Bone marrow suppression (primarily neutropenia) occurs frequently with Abraxane. 
Pri zdravilu Abraxane pogosto pride do zavrtja delovanja kostnega mozga (večinoma nevtropenija).
This multi-centre trial was conducted in patients with metastatic breast cancer, who were treated every 3 weeks with single-agent paclitaxel, either as solvent-based paclitaxel 175 mg/m2 given as a 3-hour infusion with premedication to prevent hypersensitivity (N = 225), or as Abraxane 260 mg/m2 given as a 
To raziskavo so izvedli v več centrih pri bolnikih z metastatskim rakom dojk, ki so vsake 3 tedne prejemali paklitaksel kot samostojno zdravilo, ali kot paklitaksel na bazi topila v odmerku 175 mg/m2
What Abraxane is 
Kaj je zdravilo Abraxane
In general, the frequency and severity of neurotoxicity was dose-dependent in patients receiving Abraxane. 
Na splošno je bila pri bolnikih, ki so prejemali zdravilo Abraxane, pogostnost in resnost nevrotoksičnosti odvisna od odmerka.
Rare: Cystoid macular oedema2 
Redki: cistoidni makularni edem2
Some people may feel tired or dizzy after being given Abraxane. 
Po uporabi zdravila Abraxane so lahko nekateri ljudje utrujeni ali omotični.
Abraxane(125 mg/m2)/ 
Zdravilo Abraxane (125 mg/m2)/ gemcitabin gemcitabin